Business Wire

Cleveland Diagnostics Announces Inclusion of IsoPSA® in National Comprehensive Cancer Network® Guidelines for Prostate Cancer Early Detection

CLEVELAND--(BUSINESS WIRE)--Cleveland Diagnostics, Inc., a clinical-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, announced today that its ...
Business Wire

Cleveland Diagnostics Presents New Data Supporting the Clinical Validation and Clinical Utility of IsoPSA at the 2021 Annual Meeting of American Urological Association

IsoPSA clinically validated in a study of over 1000 patients and demonstrates significant clinical utility in a study of 900 patients in a real-world setting CLEVELAND--(BUSINESS WIRE)--Cleveland ...
USA Today

Changing the Shape of Prostate Cancer Detection

About 1 in 8 men will be diagnosed with prostate cancer in their lifetime, but the screening process for this relatively common cancer isn’t always straightforward. Diagnosis can be a drawn-out and ...
Yahoo

Cleveland Diagnostics wins FDA nod for prostate cancer test

Cleveland Diagnostics said Monday it received Food and Drug Administration approval for a test that analyzes the structure of protein biomarkers in the blood for prostate cancer signals, to aid in ...
ascopubs.org

The risk of prostate cancer diagnosis in men with an elevated PSA but low IsoPSA.

Update from the PSMA-dRT trial: A randomized phase III trial of PSMA-PET prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer. Test results of patients ...
FiercePharma

Cleveland Diagnostics re-ups prostate-specific antigen test push in 'A PSA on PSA'

In tandem with September’s Prostate Cancer Awareness Month, Cleveland Diagnostics is kicking off a campaign to boost awareness of and education around screening tests for the disease. The flagship ...
Odessa American

Cleveland Diagnostics, Inc. Raises Over $19 Million in Financing

Cleveland Diagnostics, Inc., a clinical-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, announced today that it has closed a Series D round ...
BioWorld

Updated guidelines add Oncotype Dx GPS and Isopsa for prostate cancer decision-making

As the American Urological Association (AUA) annual meeting prepares to kick off on May 12, newly published prostate cancer guidelines recommend two tests to help clinicians and patients determine the ...
FierceBiotech

Next-gen prostate cancer test maker Cleveland Diagnostics rocks to $75M fundraising

Cleveland Diagnostics, maker of a prostate cancer screening test, has raised more than $75 million in growth capital funds to expand its approach to additional tumors. The financing was led by Novo ...
Crain's Cleveland Business

Cleveland Diagnostics raises more than $19 million in financing

Cleveland Diagnostics Inc., a clinical-stage company that is developing diagnostic tests for the early detection of cancers, said it has closed a Series D financing round of $17.4 million. The round ...
Morningstar

Michael Iskra Appointed CEO of Cleveland Diagnostics to Drive Strategic & Accelerated Growth Following FDA Approval of Its IsoPSA Assay

Cofounding CEO Arnon Chait to remain with company as Chief Innovation Officer Cleveland Diagnostics, Inc., a pioneering, commercial-stage precision oncology company, has named Michael Iskra as its new ...